View Post

Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: The PARP inhibitor veliparib increased progression-free survival (PFS) in women with hormone receptor (HR)-positive breast cancer and triple-negative breast cancer (TNBC) who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694), presented during the 2020 ESMO Breast Cancer Virtual Meeting. “In both subgroups, …